EMA announces public hearing on quinolone and fluoroquinolone medicines

News Category: Regulatory news

Date: 10/04/2018

The European Medicines Agency (EMA) has opened registration for its next public hearing which will take place on 13 June 2018 at the EMA’s offices in London. The public hearing will provide patients, healthcare professionals and other stakeholders with the opportunity to share experience with quinolones and fluoroquinolones, a class of antibiotics widely prescribed in the EU.

The public hearing is part of a review being carried out by EMA’s safety committee, the Pharmacovigilance Risk Assessment Committee (or PRAC).

Further details, including practical information on the public hearing process, are available from the EMA's website.

« Back